Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc
January 23, 2023 09:22 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company...
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2022
January 19, 2023 17:05 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., Jan. 19, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company...
Bioasis Technologies Inc. Mails Management Information Circular for Annual and Special Meeting of Securityholders
January 11, 2023 17:05 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company...
Bioasis Technologies Inc. Announces Amendments to Arrangement Agreement with Midatech Pharma plc
December 19, 2022 07:47 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., Dec. 19, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company...
Bioasis Technologies Inc. Announces Shareholder Webinar
December 14, 2022 20:00 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., Dec. 14, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI) (OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company...
Bioasis Technologies Inc. Announces Merger with Midatech Pharma plc
December 13, 2022 12:29 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company...
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2022
October 28, 2022 17:18 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., Oct. 28, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company...
Bioasis Technologies Inc. Announces Stock Option Grants
August 08, 2022 17:47 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., Aug. 08, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company...
Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A
July 29, 2022 17:23 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., July 29, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary...
Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets
June 16, 2022 07:50 ET
|
Bioasis Technologies Inc.
Phase 2 ready assets transform Bioasis into a clinical stage company with a multi-asset pipeline focused on rare and orphan drug indications Unique approach to neurodegeneration targeting...